Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451

Cancer Research

Volumn 65, Issue 3, 2005, Pages 957-966

  Roberts, W Gregory ^a   Whalen, Pamela M ^a   Soderstrom, Erik ^a   Moraski, Garrett ^a,b   Lyssikatos, Joseph P ^a,b   Wang, Huifen F ^a   Cooper, Beth ^a   Baker, Deborah A ^a   Savage, Douglas ^a   Dalvie, Deepak ^a   Atherton, James A ^a   Ralston, Sherry ^a   Szewc, Ruby ^a   Kath, John C ^a   Lin, Jing ^a   Soderstrom, Cathy ^a   Tkalcevic, George ^a   Cohen, Bruce D ^a   Pollack, Vince ^a,b   Barth, Wayne ^a,b   Hungerford, Will ^a   Ung, Ethan ^a   more..

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 [5 (2 METHOXYETHOXY)BENZOIMIDAZOL 1 YL]QUINOLIN 8 YL]PIPERIDIN 4 YLAMINE; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; CP 673451; CYTOTOXIC AGENT; FIBROBLAST GROWTH FACTOR RECEPTOR 2; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CANCER INHIBITION; COLON CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TUMOR LEVEL; FEMALE; GLIOBLASTOMA; LUNG CARCINOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; CELL GROWTH PROCESSES; FEMALE; GLIOBLASTOMA; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; QUINOLINES; RATS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 13444257366     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Folkman J. Antiangiogenesis: new concept for theory of solid tumors. Ann Surg 1972;175:409-16.
2. Folkman J. Tumor angiogenesis. In: Klein G, Weinhouse S, editors. Adv Cancer Res. 11008th ed. San Diego: Academic Press; 1985. p. 175-203.
3. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-4.
4. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7.
5. Carmeliet P, Jain RK. Angiogenesis and cancer in other diseases. Nature 2000;407:249-57.
6. Hermanson M, Funa K, Hartman M, et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992;52:3213-9.
7. Heldin C-H, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79:1283-316.
8. Betsholtz C, Karlsson L, Lindahl P. Developmental roles of platelet-derived growth factors. BioEssays 2001;23:494-507.
9. Yarden Y, Escobedo JA, Kuang W-J, et al. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature 1986;323:226-32.
10. Ostman A, Heldin C-H. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res 2001;80:1-38.
11. Holmgren L, Glaser A, Pfeifer-Ohlsson S, Ohlsson R. Angiogenesis during human extraembryonic development involves the spatiotemporal control of PDGF ligand and receptor gene expression. Development 1991;113:749-54.
12. Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B and PDGFR-β in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessels formation in the mouse. Development 1999;126:3047-55.
13. Shinbrot E, Peters KG, Williams LT. Expression of the platelet-derived growth factor β-receptor during organogenesis and tissue differentiation in the mouse embryo. Dev Dyn 1994;199:169-75.
14. Leveen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C. Mice deficient in PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 1994:8:1875-87.
15. Soriano P. Abnormal kidney development and hematological disorders on PDGF β-receptor mutant mice. Genes Dev 1994;8:1888-96.
16. Lindahl P, Hellstrom M, Kalen M, et al. Paracrine PDGF-B/PDGF-R β signaling controls mesangial cell development in kidney glomeruli. Development 1998;125:3301-12.
17. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997;277:242-5.
18. Hirschi KK, D'Amore PA. Pericytes in the microvasculature. Cardiovasc Res 1996;32:687-98.
19. Allt G, Lawrenson JG. Pericytes: cell biology and pathology. Cells Tissues Organs 2001;169:1-11.
20. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160:985-1000.
21. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003;314:15-23.
22. Bhardwaj B, Klassen J, Cossette N, et al. Localization of platelet-derived growth factor β receptor expression in the periepithelial stroma of human breast carcinoma. Clin Cancer Res 1996;2:773-82.
23. Sundberg C, Branting M, Bengt G, Rubin K. Tumor cell and connective tissue cell interactions in human colorectal adenocarcinoma. Am J Pathol 1997;151:479-92.
24. Kawai T, Hiroi S, Torikata C. Expression in lung carcinomas of platelet-derived growth factor and its receptors. Lab Invest 1997;77:431-6.
25. Fudge K, Bostwick DG, Stearns ME. Platelet-derived growth factor A and B chains and the α and β receptors in prostatic intraepithelial neoplasia. Prostate 1996;29:282-6.
26. Hermanson M, Funa K, Koopman J, et al. Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor α receptor expression in human malignant gliomas. Cancer Res 1996;56:164-71.
27. Plate KH, Breier G, Farrell CL, Risau W. Platelet-derived growth factor receptor-β is induced during tumor development and up-regulated during tumor progression in endothelial cells in human gliomas. Lab Invest 1992;67:529-34.
28. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin C-H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988-95.
29. Wolff NC, Randle DE, Wegorin MJ, Minna JD, Ilaria RL. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer. Clin Cancer Res 2004;10:3528-34.
30. Knick VC, Eberwein DJ, Miller CG. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J Natl Cancer Inst 1995;87:1072-7.
31. Yamori T, Sata S, Chikazawa H, Kadota T. Antitumor efficacy of paclitaxel against human lung cancer xenografts. Jpn J Cancer Res 1997;88:1205-10.
32. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
33. Deveraux QL, Aza-Blanc P, Wagner KW, Bauerschlag D, Cooke MP, Hampton GM. Exposing oncogenic dependencies for cancer drug target discovery and validation using RNAi. Semin Cancer Biol 2003;13:293-300.
34. Im SA, Kim JS, Gomez-Manzano C, et al. Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF. Br J Cancer 2001;84:1252-7.
35. Yu JC, Lokker NA, Hollenbach S, et al. Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury. J Pharmacol Exp Ther 2001;298:1172-8.
36. Zaman GJ, Vink PM, van den Doelen AA, Veeneman GH, Theunissen HJ. Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor β-receptor (β-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases. Biochem Pharmacol 1999;37:57-64.
37. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95.
38. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106.
39. Laird AD, Christensen JG, Li G, et al. SU6668 inhibits Flk-1/KDR and PDGFR-β in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 2002;16:681-90.
40. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
41. Manley PW, Cowan-Jacob SW, Buchdunger E, et al. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer 2002;38:S19-27.
42. Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002;1:117-23.
43. Claesson-Welsh L, Eriksson A, Moren A, et al. cDNA cloning and expression of a human platelet-derived growth factor (PDGF) receptor specific for B-chain-containing PDGF molecules. Mol Cell Biol 1988;8:3476-86.
44. Herren B, Weyer KA, Rouge M, Lotscher P, Pech M. Conservation in sequence and affinity of human and rodent PDGF ligands and receptors. Biochim Biophys Acta 1993;1173:294-302.
45. Beebe JS, Jani JP, Knauth E, et al. Pharmacological characterization of CP-547,632, a novel vasular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res 2003;63:7301-9.
46. Bilodeau MT, Fraley ME, Hartman GD. Kinase insert domain-containing receptor tyrosine kinase inhibitors as antiangiogenic agents. Expert Opin Investig Drugs 2002;11:737-45.
47. Kilic T, Alberta JA, Zdunek PR, et al. Intracranial inhibition of platelet derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 2000;60:5143-50.
48. Fleming TP, Saxena A, Clark WC, et al. Amplification and/or overexpression of platelet-derived growth receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 1992;52:4550-3.
49. Saito Y, Haendeler J, Hojo Y, U Yamamoto K, Berk BC. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol 2001;21:6387-94.
50. Wang D, Huang H-JS, Kazlauskas A, Cavenee WK. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through activation of phosphatidylinositol 3-kinase. Cancer Res 1999;59:1464-72.
51. Pietras K, Rubin K, Sjoblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62:5476-84.
52. Laskey JA, Brody AR. Interstitial fibrosis and growth factors. Environ Health Perspect 2000;108:751-62.
53. Bult H. Restenosis: a challenge for pharmacology. Trends Pharmacol Sci 2000;21:274-9.
54. Manley PW, Martiny-Baron G, Schlaeppi JM, Wood JM. Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs 2002;11:1715-36.